Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results